Navigation Links
Shire Changes its NASDAQ Ticker Symbol to SHPG
Date:7/9/2012

DUBLIN, Ireland, July 9, 2012 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that the NASDAQ ticker symbol for Shire's American Depositary Shares ("ADSs") will change from "SHPGY" to "SHPG" on and from the opening of NASDAQ trading on July 11, 2012.

Each ADS continues to represent 3 ordinary shares of Shire plc.

The London Stock Exchange ticker symbol for Shire plc's ordinary shares remains "SHP".

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

For further information please contact:

         Investor Relations     Eric Rojas                         erojas@shire.com          +1-781-482-0999     Sarah Elton-Farr                  seltonfarr@shire.com     +44(0)1256-894157


'/>"/>
SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
2. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
5. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
6. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
7. Why Medicare Carrier Proposes Major Changes in the Handling of Code Stacked Molecular Test Claims is Topic of December 20 Audio Conference
8. CSL Behring Awards LEAD Grant to Patient Organizations to Educate Constituents on State Insurance Exchanges
9. NYSE Companies and NASDAQ Companies June 7th Investor Presentations Now Available at RetailInvestorConferences.com
10. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
11. Sequenom Named to NASDAQ Global Select Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec 5, 2016 Research and ... "Biomarkers - Technologies, Markets and Companies" to their offering. ... , , ... their discovery using various -omics technologies such as proteomics and metabolomics. ... new tests are also based on biomarker. Currently the ...
(Date:12/5/2016)... 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the ... and Safety Monitoring Board (DSMB) for the Company,s ... (CVD) patients has completed a second planned safety ... as planned without any modifications. The DSMB reviewed ... or efficacy concerns were identified. The DSMB will ...
(Date:12/4/2016)... ... December 02, 2016 , ... A proposed five-year extension ... federally funded research and development is welcome news for the photonics community, say ... , As part of the National Defense Authorization Act (NDAA) compromise agreement finalized ...
(Date:12/2/2016)... 2016 More than $4.3 million was raised last ... DHMD ). The gala was held at the American Museum ... and honored Alan Alda and ... and medicine and the public understanding of science. Since the ... event has raised $40 million for the Laboratory,s research and ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
(Date:6/27/2016)... 27, 2016 Research and Markets has announced ... report to their offering. ... to grow at a CAGR of 12.28% during the ... on an in-depth market analysis with inputs from industry experts. The ... coming years. The report also includes a discussion of the key ...
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
Breaking Biology News(10 mins):